AstraZeneca has secured a key regulatory win in its effort to reclaim the lead in the BTK inhibitor market, with the FDA approving its combination of Calquence plus Venclexta as the first all-oral, ...

Please provide your email address to receive an email when new articles are posted on . The combination is the first all-oral, fixed duration treatment for patients with CLL and or small lymphocytic ...

AMPLIFY showed improved PFS for acalabrutinib/venetoclax versus FCR or BR, with HR 0.65 and median PFS not estimable versus 47.6 months at 42.6-month follow-up ...

The FDA approved acalabrutinib (Calquence) plus venetoclax (Venclexta) for previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma as the first all-oral, fixed-duration ...

Several potentially practice-changing phase 3 trials alongside promising results in emerging strategies in chronic lymphocytic leukemia (CLL) presented at the 2025 American Society of Hematology ...

People often blame social media algorithms that prioritize extreme content for increasing political polarization, but this effect has been difficult to prove. Only the platform owners have access to ...

Experts explore the evolving landscape of chronic lymphocytic leukemia treatment, highlighting targeted therapies, MRD strategies, and future innovations. In this episode of Treating Together, host ...

Targeted therapies, including BTK inhibitors and venetoclax, have replaced chemoimmunotherapy as the first-line standard for CLL, emphasizing patient preference and risk factors in treatment decisions ...

Learn how recommendation algorithms, streaming recommendations, and social media algorithms use content recommendation systems to deliver personalized recommendations. Pixabay, TungArt7 From movie ...

In the world of oncology drug development, the standard playbook is simple: Race to earlier lines of treatment, where patient populations are larger. But Eli Lilly is flipping that script with its ...

BRUIN CLL-313 is a randomized, open-label, global phase III study comparing the efficacy and safety of pirtobrutinib, a highly selective, noncovalent Bruton tyrosine kinase inhibitor (BTKi), against ...